Skip to content

Study · Observational study · n = 65 · 2013

3 results

Comparison of the therapeutic effect of teriparatide with that of combined vertebroplasty with antiresorptive agents for the treatment of new-onset adjacent vertebral compression fracture after percutaneous vertebroplasty.

Su CH, Tu PH, Yang TC, Tseng YY

Journal of spinal disorders & techniques1 Jun 2013Cited by 23 (Europe PMC)

PMID22134732 (opens in a new tab)DOI10.1097/bsd.0b013e31823f6298 (opens in a new tab)PepBankPUB-22134732
Publisher pagePubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

3 results from studies that gave the peptide. 3 results from people.

  1. 01HumanObservational studyEfficacy outcome

    In patients with adjacent fractures after vertebroplasty, authors reported lower new fracture odds with teriparatide, although the confidence interval included no difference.

    In plain wordsAfter vertebroplasty, authors reported fewer fractures with teriparatide than antiresorptives plus repeated vertebroplasty, although the confidence interval included no difference.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    DecreaseNew vertebral compression fractures
    Study

    n = 65

    Comparator
    Antiresorptive agents with repeated vertebroplasty
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    Dose not stated · At least 18 months of treatment; mean follow-up 22.56 monthsAs given in this study (human).

    Measurements

    Odds ratio
    0.18 ratio
    new VCFs

    Source sentences

    Summary
    Teriparatide significantly reduced the risk of new VCFs after vertebroplasty (odds ratio=0.18; 95% confidence interval, 0.02-1.64).
    2 context sentences
    Summary · context
    In group A, only 1 new-onset VCF occurred during the mean follow-up period of 22.56 months.
    Summary · context
    Comparing a prospective group of 32 patients, who underwent percutaneous vertebroplasty (PVP) and who were treated with teriparatide for at least 18 months after a new-onset adjacent vertebral compression fracture (VCF), and compared it with a retrospective group of 33 patients, who received antires…
  2. 02HumanObservational studyEfficacy outcome

    In patients with adjacent fractures after vertebroplasty, lumbar BMD increased more with teriparatide than with antiresorptive treatment.

    In plain wordsAfter vertebroplasty, spine bone density increased more with teriparatide than with antiresorptive treatment.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    IncreaseLumbar spine BMD
    Study

    n = 65

    Comparator
    Antiresorptive agents with repeated vertebroplasty
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    Dose not stated · 18 monthsAs given in this study (human).

    Measurements

    BMD increase
    26.32%
    teriparatide
    BMD increase
    4.62%
    antiresorptives

    Source sentences

    Summary
    The increase of lumbar spine BMD was 26.32% after 18 months of treatment with teriparatide and 4.62% after 18 months of treatment with antiresorptive agents.
    1 context sentence
    Summary · context
    Comparing a prospective group of 32 patients, who underwent percutaneous vertebroplasty (PVP) and who were treated with teriparatide for at least 18 months after a new-onset adjacent vertebral compression fracture (VCF), and compared it with a retrospective group of 33 patients, who received antires…
  3. 03HumanObservational studyEfficacy outcome

    In patients with adjacent fractures after vertebroplasty, pain scores decreased more with teriparatide than with antiresorptive treatment at follow-up.

    In plain wordsAfter vertebroplasty, pain scores decreased more with teriparatide than with antiresorptive treatment.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    DecreaseVisual analogue pain score
    Study

    n = 65

    Comparator
    Antiresorptive agents with repeated vertebroplasty
    Outcome group
    Pain · Musculoskeletal
    Studied dose
    Dose not stated · 18 monthsAs given in this study (human).

    Measurements

    Visual analogue scale score
    8.03 score
    teriparatide, baseline
    Visual analogue scale score
    1.37 score
    teriparatide, 18-month follow-up
    Visual analogue scale score
    7.91 score
    antiresorptive, baseline
    Visual analogue scale score
    4.23 score
    antiresorptive, 18-month follow-up

    Source sentences

    Summary
    In addition, at the 18-month follow-up, mean visual analogue scale scores had decreased from 8.03±1.97-1.37±0.52 in the teriparatide group and from 7.91±1.95-4.23±1.21 in the antiresorptive group.
    1 context sentence
    Summary · context
    Comparing a prospective group of 32 patients, who underwent percutaneous vertebroplasty (PVP) and who were treated with teriparatide for at least 18 months after a new-onset adjacent vertebral compression fracture (VCF), and compared it with a retrospective group of 33 patients, who received antires…

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:26 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.